Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $55,679 | 2 | 86.4% |
| Consulting Fee | $8,300 | 4 | 12.9% |
| Travel and Lodging | $288.80 | 1 | 0.4% |
| Food and Beverage | $153.14 | 2 | 0.2% |
| Education | $14.20 | 6 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $59,859 | 6 | $0 (2022) |
| Shire North American Group Inc | $4,500 | 2 | $0 (2018) |
| Celgene Corporation | $62.79 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $62.79 | 1 | Celgene Corporation ($62.79) |
| 2022 | $28,773 | 2 | Eli Lilly and Company ($28,773) |
| 2021 | $28,706 | 1 | Eli Lilly and Company ($28,706) |
| 2020 | $5.49 | 3 | Travere Therapeutics, Inc. ($5.49) |
| 2019 | $0.83 | 1 | Retrophin, Inc. ($0.83) |
| 2018 | $4,379 | 4 | Eli Lilly and Company ($2,379) |
| 2017 | $2,508 | 3 | Shire North American Group Inc ($2,500) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/16/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $62.79 | General |
| Category: Neuroscience | ||||||
| 11/22/2022 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 10/24/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $26,973.00 | Research |
| 04/21/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $28,706.40 | Research |
| Study: MULTICENTER, OPEN-LABEL PK STUDY OF MIRIKIZUMAB IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | ||||||
| 02/12/2020 | Travere Therapeutics, Inc. | (820) Cholbam (Drug) | Education | In-kind items and services | $1.83 | General |
| Category: Hepatology | ||||||
| 02/12/2020 | Travere Therapeutics, Inc. | (820) Cholbam (Drug) | Education | In-kind items and services | $1.83 | General |
| Category: Hepatology | ||||||
| 02/12/2020 | Travere Therapeutics, Inc. | (820) Cholbam (Drug) | Education | In-kind items and services | $1.83 | General |
| Category: Hepatology | ||||||
| 11/04/2019 | Retrophin, Inc. | (820) Cholbam (Drug) | Education | In-kind items and services | $0.83 | General |
| Category: Hepatology | ||||||
| 11/28/2018 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 10/25/2018 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $288.80 | General |
| 10/25/2018 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $90.35 | General |
| 10/23/2018 | Shire North American Group Inc | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 10/17/2017 | Retrophin, Inc. | (820) Cholbam (Drug) | Education | In-kind items and services | $3.94 | General |
| Category: Hepatology | ||||||
| 06/28/2017 | Shire North American Group Inc | — | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| 05/23/2017 | Retrophin, Inc. | (820) Cholbam (Drug) | Education | In-kind items and services | $3.94 | General |
| Category: Hepatology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MULTICENTER, OPEN-LABEL PK STUDY OF MIRIKIZUMAB IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | Eli Lilly and Company | $28,706 | 1 |
About Athos Bousvaros, MD, MPH
Athos Bousvaros, MD, MPH is a Pediatric Gastroenterology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528174885.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Athos Bousvaros, MD, MPH has received a total of $64,436 in payments from pharmaceutical and medical device companies, with $62.79 received in 2024. These payments were reported across 15 transactions from 5 companies. The most common payment nature is "" ($55,679).
Practice Information
- Specialty Pediatric Gastroenterology
- Location Boston, MA
- Active Since 08/21/2006
- Last Updated 07/08/2007
- Taxonomy Code 2080P0206X
- Entity Type Individual
- NPI Number 1528174885
Products in Payments
- ZEPOSIA (Drug) $62.79
- (820) Cholbam (Drug) $14.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Gastroenterology Doctors in Boston
Dr. Claire Zar-Kessler, Md, MD
Pediatric Gastroenterology — Payments: $52,051
Alessio Fasano, Md, MD
Pediatric Gastroenterology — Payments: $41,795
Maureen Jonas, Md, MD
Pediatric Gastroenterology — Payments: $27,311
Dr. Jocelyn Silvester, Md Phd, MD PHD
Pediatric Gastroenterology — Payments: $17,272
Dr. Samuel Nurko, Md, MD
Pediatric Gastroenterology — Payments: $17,160
Dr. Navneet Virk Hundal, M.d, M.D
Pediatric Gastroenterology — Payments: $8,843